OBI 898
Alternative Names: OBI-898; SSEA-4 monoclonal antibody - OBI PharmaLatest Information Update: 28 Feb 2023
At a glance
- Originator OBI Pharma
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cancer in Taiwan (Parenteral)
- 01 Jan 2019 Preclinical trials in Cancer in Taiwan (Parenteral) before January 2019 (OBI Pharma pipeline, January 2019)